A Phase 2 interventional study of VGX-3100 and Imiquimod 5% Cream in Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia and Vulvar Intraepithelial Neoplasia (VIN), sponsored by Inovio Pharmaceuticals. Completed at 15 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-25.
Sponsored by Inovio Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Squamous Intraepithelial Lesions with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Squamous Intraepithelial Lesions · United States.
Among the 44 studies in Squamous Intraepithelial Lesions with a site in United States, this one is the 24th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2017, is one of 19 in phase 2, and was the 24th registered.
104 studies on the registry are indexed under Squamous Intraepithelial Lesions; 36 are open to participants now.
Browse Squamous Intraepithelial Lesions studies →7 of the 44 studies in Squamous Intraepithelial Lesions with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States, Puerto Rico
Ages 21+
The Center for Clinical and Cosmetic Research · Sites in United States
Ages 18+
The Center for Clinical and Cosmetic Research · Sites in United States
Ages 18+
Frantz Viral Therapeutics, LLC · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Squamous Intraepithelial Lesions studies recruiting now, 11 (48%) set no upper age limit and 11 (48%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 21 · Phase 3 6 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 71 across 73 interventional studies indexed under Squamous Intraepithelial Lesions.
Median enrollment 48 across the 39 interventional studies, 195 across the 5 observational. Of the 34 that completed or were terminated, 19 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 44 have an industry lead sponsor. The 10 most frequent:
Inovio Pharmaceuticals is the lead sponsor of 31 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 10 (71%) have results posted.
Inovio Pharmaceuticals has 4 studies filed under Squamous Intraepithelial Lesions — fewer than ten, so there is no comparison to draw.
5 of the studies in Squamous Intraepithelial Lesions with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05381597Phase 3Boston University5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer | 2027-06 |
| NCT07931664The Center for Clinical and Cosmetic ResearchEvaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. | 2026-11 |
| NCT06206564Frantz Viral Therapeutics, LLCArtesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants | 2026-12-31 |
| NCT07886203Mayo ClinicEvaluation of a Point-of-Care, AI-Powered Spectroscopy Device for Triage of Suspicious Vulvar Lesions: A Pilot Study | 2027-09-30 |
| NCT06949800University of California, San FranciscoCASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Squamous Intraepithelial Lesions with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar high-grade squamous intraepithelial lesion (HSIL) [vulval intraepithelial neoplasia 2 or 3 (VIN 2 or VIN 3)] associated with human papilloma virus (HPV) types 16 and/or 18. VGX-3100 is being assessed as an alternative to surgery with the potential to clear the underlying HPV infection. For more information visit our study website at: www.VINresearchstudy.com
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with histologically confirmed vulvar high-grade squamous intraepithelial lesion (HSIL) associated with human papilloma virus (HPV) 16 and/or 18, received four doses of 6 mg VGX-3100 as an intramuscular (IM) injection on Day 0, Week 4, Week 12, and Week 24 followed by electroporation (EP) using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52.
Biological: VGX-3100 · Device: CELLECTRA™ 2000
Participants with histologically confirmed vulvar HSIL associated with HPV-16 and/or 18, received four doses of 6 mg VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 24 followed by EP using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52. In addition, participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
Biological: VGX-3100 · Drug: Imiquimod 5% Cream · Device: CELLECTRA™ 2000
One milliliter (1 mL) VGX-3100 injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24.
Participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
IM injection of VGX-3100 was followed by EP with the CELLECTRA™ 2000 device.
Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples
A treatment responder for the primary endpoint was defined as a participant with no histologic evidence of vulvar HSIL (normal tissue or vulvar low grade squamous intraepithelial lesions (LSIL) \[vulval intraepithelial neoplasia 1 (VIN1)\] or condyloma) and no evidence of HPV-16 or HPV-18 (i.e., elimination of the specific genotypes \[16, 18, or both\]) in vulvar tissue at evaluation and who did not receive any non-study related treatment for vulvar HSIL. All lesions were evaluated for histologic evidence of vulvar HSIL or evidence of HPV-16/18 in vulvar tissue.
Time frame: Week 48
Percentage of Participants With at Least One Local and Systemic Treatment-emergent Adverse Event (TEAE) During 7 Days Following Each Dose
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a product whether or not considered related to the use of the product. A TEAE was defined per protocol as any AE with onset after the administration of study medication through the end of the study (i.e., study discharge).
Time frame: 7 days following each dose: Day 0 (Days 0 to 7), Week 4 (Days 22 to 28), Week 12 (Days 78 to 84), Week 24 (Days 162 to 168), and Week 52 (Days 358 to 364)
Percentage of Participants With Adverse Events (AEs)
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a product whether or not considered related to the use of the product.
Time frame: From baseline up to Week 100
Percentage of Participants With No Histologic Evidence of Vulvar HSIL
Participants with no histologic evidence of vulvar HSIL (normal tissue or vulvar LSIL \[VIN1\] or condyloma) based on histology (i.e. biopsies or excisional treatment) were considered. All lesions were evaluated for histologic evidence of vulvar HSIL.
Time frame: Week 48
Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples
Participants with no evidence of HPV-16 and/or HPV-18 indicated the clearance of the specific HPV genotypes \[16, 18, or both\]. All lesions were evaluated for evidence of HPV-16/18 in vulvar tissue.
Time frame: Week 48
Percentage of Participants With No Histologic Evidence of Vulvar HSIL or No Evidence of HPV-16/18 in Vulvar Tissue
A treatment responder for the endpoint was defined as a participant with no histologic evidence of vulvar HSIL (normal tissue or LSIL \[VIN1\] or condyloma) based on histology (i.e. biopsies or excisional treatment) or no evidence of HPV-16 or HPV-18 (i.e., elimination of the specific genotypes \[16, 18, or both\]) in vulvar tissue at evaluation and who did not receive any non-study related treatment for vulvar HSIL. All lesions were evaluated for histologic evidence of vulvar HSIL or evidence of HPV-16/18 in vulvar tissue.
Time frame: Week 48
Percentage of Participants With No Evidence of Vulvar HSIL, No Evidence of Vulvar LSIL (VIN1), and No Evidence of Condyloma on Histology
Histologic regression was defined as a participant with no histologic evidence of vulvar HSIL, no evidence of LSIL (VIN1), and no evidence of condyloma. Histologic regression of vulvar HSIL to normal tissue was assessed.
Time frame: Week 48
Percentage of Participants With No Progression of Vulvar HSIL to Vulvar Cancer
Non-progression of vulvar HSIL to vulvar cancer was evaluated from baseline to Week 48. Progression was defined as advancement to carcinoma by histology.
Time frame: From baseline up to Week 48
Percent Change From Baseline in the Cumulative Surface Area of the Acetowhite Vulvar Lesion(s)
Lesion(s), defined as areas that stain acetowhite were assessed. Analysis of qualifying lesions was defined as the change in total surface area of only lesions with both baseline and Week 48 measurements. Percent change in the cumulative surface area of the acetowhite vulvar lesion(s) was determined by the quantitative analysis of standardized prebiopsy photographic imaging of qualifying lesion(s) at Week 48 compared to baseline.
Time frame: From baseline to Week 48
Change From Baseline in Interferon-Gamma (IFN-γ) Response Magnitude
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples. Assessment of cellular immune activity was performed by IFN-γ enzyme-linked immunosorbent spot-forming (ELISpot) assay.
Time frame: Baseline; Weeks 15, 27, 48, 74, and 96
Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations
A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100.
Time frame: Weeks 15, 27, 48, 74, and 96
Change From Baseline in Flow Cytometry Response Magnitude
Assessment of cellular immune activity was measured using the application of flow cytometry for the purpose of performing a Lytic Granule Loading Assay. The Lytic Granule Loading Assay examines the following external cellular markers: cluster of differentiation 3 (CD3), CD4, CD8 (T-cell identification), CD137, CD38, and CD69 (T-cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, a change from baseline in CD8+/CD137+ PBMCs expressing Perforin+ was reported.
Time frame: Baseline; Week 27
Participants were enrolled at 20 study sites in the United States from 31 August 2017 to 18 December 2020.
| Milestone | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Started | 25 | 8 |
| Modified intent-to-treat (mitt) population | 25 | 8 |
| Safety population | 25 | 8 |
| Completed | 17 | 8 |
| Not completed | 8 | 0 |
| Withdrew: Withdrawal by subject (not related to ae) | 5 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Progressive disease | 1 | 0 |
A treatment responder for the primary endpoint was defined as a participant with no histologic evidence of vulvar HSIL (normal tissue or vulvar low grade squamous intraepithelial lesions (LSIL) \[vulval intraepithelial neoplasia 1 (VIN1)\] or condyloma) and no evidence of HPV-16 or HPV-18 (i.e., elimination of the specific genotypes \[16, 18, or both\]) in vulvar tissue at evaluation and who did not receive any non-study related treatment for vulvar HSIL. All lesions were evaluated for histologic evidence of vulvar HSIL or evidence of HPV-16/18 in vulvar tissue.
| percentage of participants | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples | 15.0 (3.2 to 37.9) | 37.5 (8.5 to 75.5) |
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a product whether or not considered related to the use of the product. A TEAE was defined per protocol as any AE with onset after the administration of study medication through the end of the study (i.e., study discharge).
| percentage of participants | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Percentage of Participants With at Least One Local and Systemic Treatment-emergent Adverse Event (TEAE) During 7 Days Following Each Dose | 84.0 (63.92 to 95.46) | 75.0 (34.91 to 96.81) |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a product whether or not considered related to the use of the product.
| percentage of participants | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 92.0 | 100 |
Participants with no histologic evidence of vulvar HSIL (normal tissue or vulvar LSIL \[VIN1\] or condyloma) based on histology (i.e. biopsies or excisional treatment) were considered. All lesions were evaluated for histologic evidence of vulvar HSIL.
| percentage of participants | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Percentage of Participants With No Histologic Evidence of Vulvar HSIL | 15.0 (3.2 to 37.9) | 37.5 (8.5 to 75.5) |
Participants with no evidence of HPV-16 and/or HPV-18 indicated the clearance of the specific HPV genotypes \[16, 18, or both\]. All lesions were evaluated for evidence of HPV-16/18 in vulvar tissue.
| percentage of participants | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples | 15.0 (3.2 to 37.9) | 50.0 (15.7 to 84.3) |
A treatment responder for the endpoint was defined as a participant with no histologic evidence of vulvar HSIL (normal tissue or LSIL \[VIN1\] or condyloma) based on histology (i.e. biopsies or excisional treatment) or no evidence of HPV-16 or HPV-18 (i.e., elimination of the specific genotypes \[16, 18, or both\]) in vulvar tissue at evaluation and who did not receive any non-study related treatment for vulvar HSIL. All lesions were evaluated for histologic evidence of vulvar HSIL or evidence of HPV-16/18 in vulvar tissue.
| percentage of participants | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Percentage of Participants With No Histologic Evidence of Vulvar HSIL or No Evidence of HPV-16/18 in Vulvar Tissue | 15.0 (3.2 to 37.9) | 50.0 (15.7 to 84.3) |
Histologic regression was defined as a participant with no histologic evidence of vulvar HSIL, no evidence of LSIL (VIN1), and no evidence of condyloma. Histologic regression of vulvar HSIL to normal tissue was assessed.
| percentage of participants | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Percentage of Participants With No Evidence of Vulvar HSIL, No Evidence of Vulvar LSIL (VIN1), and No Evidence of Condyloma on Histology | 10.0 (1.2 to 31.7) | 37.5 (8.5 to 75.5) |
Non-progression of vulvar HSIL to vulvar cancer was evaluated from baseline to Week 48. Progression was defined as advancement to carcinoma by histology.
| percentage of participants | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Percentage of Participants With No Progression of Vulvar HSIL to Vulvar Cancer | 100.0 (83.2 to 100.0) | 100.0 (63.1 to 100.0) |
Lesion(s), defined as areas that stain acetowhite were assessed. Analysis of qualifying lesions was defined as the change in total surface area of only lesions with both baseline and Week 48 measurements. Percent change in the cumulative surface area of the acetowhite vulvar lesion(s) was determined by the quantitative analysis of standardized prebiopsy photographic imaging of qualifying lesion(s) at Week 48 compared to baseline.
| percent change in surface area | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Percent Change From Baseline in the Cumulative Surface Area of the Acetowhite Vulvar Lesion(s) | 47.7 ± 249.62 | 10.5 ± 117.95 |
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples. Assessment of cellular immune activity was performed by IFN-γ enzyme-linked immunosorbent spot-forming (ELISpot) assay.
| spot forming units (SFU) per 10^6 cells | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| HPV-16 E6 (Baseline) | 1.667 (0.00 to 35.00) | 1.667 (0.00 to 8.33) |
| HPV-16 E6 (Change From Baseline at Week 15) | 0.833 (0.00 to 78.33) | 0.000 (0.00 to 43.33) |
| HPV-16 E6 (Change From Baseline at Week 27) | 0.833 (0.00 to 58.33) | 3.333 (0.00 to 36.67) |
| HPV-16 E6 (Change From Baseline at Week 48) | 0.833 (0.00 to 56.67) | 0.000 (0.00 to 3.33) |
| HPV-16 E6 (Change From Baseline at Week 74) | 1.667 (0.00 to 30.00) | 0.000 (0.00 to 25.00) |
| HPV-16 E6 (Change From Baseline at Week 96) | 1.667 (0.00 to 38.33) | 0.833 (0.00 to 8.33) |
| HPV-16 E7 (Baseline) | 1.667 (0.00 to 15.00) | 0.000 (0.00 to 1.67) |
| HPV-16 E7 (Change From Baseline at Week 15) | 3.333 (0.00 to 43.33) | 1.667 (0.00 to 56.67) |
| HPV-16 E7 (Change From Baseline at Week 27) | 3.333 (0.00 to 71.67) | 6.667 (0.00 to 40.00) |
| HPV-16 E7 (Change From Baseline at Week 48) | 1.667 (0.00 to 31.67) | 1.667 (0.00 to 25.00) |
| HPV-16 E7 (Change From Baseline at Week 74) | 1.667 (0.000 to 15.00) | 0.833 (0.00 to 21.67) |
| HPV-16 E7 (Change From Baseline at Week 96) | 0.000 (0.000 to 3.33) | 0.000 (0.00 to 0.00) |
| HPV-18 E6 (Baseline) | 0.000 (0.00 to 6.67) | 0.000 (0.00 to 6.67) |
| HPV-18 E6 (Change From Baseline at Week 15) | 19.167 (0.00 to 593.33) | 10.000 (1.67 to 123.33) |
| HPV-18 E6 (Change From Baseline at Week 27) | 10.833 (0.00 to 908.33) | 5.000 (0.00 to 146.67) |
| HPV-18 E6 (Change From Baseline at Week 48) | 14.167 (0.00 to 566.67) | 3.333 (0.00 to 80.00) |
| HPV-18 E6 (Change From Baseline at Week 74) | 8.333 (0.00 to 925.00) | 9.167 (0.00 to 45.00) |
| HPV-18 E6 (Change From Baseline at Week 96) | 20.000 (0.00 to 63.33) | 19.167 (1.67 to 48.33) |
| HPV-18 E7 (Baseline) | 0.000 (0.00 to 11.67) | 0.000 (0.00 to 3.33) |
| HPV-18 E7 (Change From Baseline at Week 15) | 2.500 (0.00 to 51.67) | 3.333 (0.00 to 16.67) |
| HPV-18 E7 (Change From Baseline at Week 27) | 1.667 (0.00 to 33.33) | 6.667 (0.00 to 43.33) |
| HPV-18 E7 (Change From Baseline at Week 48) | 1.667 (0.00 to 51.67) | 0.000 (0.00 to 21.67) |
| HPV-18 E7 (Change From Baseline at Week 74) | 1.667 (0.00 to 20.00) | 0.000 (0.00 to 6.67) |
| HPV-18 E7 (Change From Baseline at Week 96) | 3.333 (0.00 to 5.00) | 4.167 (0.00 to 13.33) |
A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100.
| reciprocal endpoint titer | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Anti-HPV-16 (Week 15) | 7.3 ± 3.22 | 13.1 ± 2.89 |
| Anti-HPV-16 (Week 27) | 9.6 ± 3.24 | 15.0 ± 3.07 |
| Anti-HPV-16 (Week 48) | 15.9 ± 3.33 | 17.2 ± 3.06 |
| Anti-HPV-16 (Week 74) | 14.5 ± 3.31 | 6.1 ± 2.80 |
| Anti-HPV-16 (Week 96) | 37.0 ± 3.13 | 11.4 ± 2.85 |
| Anti-HPV-18 (Week 15) | 24.8 ± 3.73 | 133.7 ± 4.32 |
| Anti-HPV-18 (Week 27) | 44.7 ± 3.67 | 89.4 ± 4.85 |
| Anti-HPV-18 (Week 48) | 69.3 ± 3.87 | 133.7 ± 4.36 |
| Anti-HPV-18 (Week 74) | 83.2 ± 3.98 | 45.0 ± 4.23 |
| Anti-HPV-18 (Week 96) | 2.9 ± 1.86 | 2.2 ± 1.61 |
Assessment of cellular immune activity was measured using the application of flow cytometry for the purpose of performing a Lytic Granule Loading Assay. The Lytic Granule Loading Assay examines the following external cellular markers: cluster of differentiation 3 (CD3), CD4, CD8 (T-cell identification), CD137, CD38, and CD69 (T-cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, a change from baseline in CD8+/CD137+ PBMCs expressing Perforin+ was reported.
| SFU/10^6 PBMC | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Baseline | 0.150 (0.00 to 14.50) | 1.250 (0.00 to 3.35) |
| Change from Baseline at Week 27 | 0.000 (0.00 to 18.70) | 0.000 (0.00 to 7.70) |
Collected over From the first injection up to Week 100. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VGX-3100 + EP | 0/25 (0%) | 3/25 (12%) | 23/25 (92%) |
| VGX-3100 + EP + Imiquimod | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Event | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/25 | 0/8 |
| UlcerGeneral disorders | 1/25 | 0/8 |
| CellulitisInfections and infestations | 1/25 | 0/8 |
| Pulmonary massRespiratory, thoracic and mediastinal disorders | 1/25 | 0/8 |
| Event | VGX-3100 + EP | VGX-3100 + EP + Imiquimod |
|---|---|---|
| Injection site painGeneral disorders | 18/25 | 6/8 |
| FatigueGeneral disorders | 14/25 | 4/8 |
| MyalgiaMusculoskeletal and connective tissue disorders | 12/25 | 4/8 |
| NauseaGastrointestinal disorders | 10/25 | 3/8 |
| Injection site bruisingGeneral disorders | 10/25 | 0/8 |
| HeadacheNervous system disorders | 10/25 | 3/8 |
| Injection site swellingGeneral disorders | 9/25 | 3/8 |
| Injection site erythemaGeneral disorders | 8/25 | 3/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/25 | 3/8 |
| PyrexiaGeneral disorders | 1/25 | 2/8 |
mITT population included all participants who received at least 1 dose of VGX-3100 + EP (with or without imiquimod) and had an analysis endpoint of interest.
| Age, Continuous(years) | VGX-3100 + EP | VGX-3100 + EP + Imiquimod | Total |
|---|---|---|---|
| Mean | 50.2 ± 12.86 | 45.4 ± 9.13 | 49.1 ± 12.11 |
| Sex: Female, Male(Participants) | VGX-3100 + EP | VGX-3100 + EP + Imiquimod | Total |
|---|---|---|---|
| Female | 25 | 8 | 33 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | VGX-3100 + EP | VGX-3100 + EP + Imiquimod | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 23 | 8 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | VGX-3100 + EP | VGX-3100 + EP + Imiquimod | Total |
|---|---|---|---|
| Race — Black or African | 3 | 0 | 3 |
| Race — White | 21 | 8 | 29 |
| Race — Other | 1 | 0 | 1 |
| Region of Enrollment(participants) | VGX-3100 + EP | VGX-3100 + EP + Imiquimod | Total |
|---|---|---|---|
| United States | 25 | 8 | 33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Jul 2020, 34 months.
Results were first posted in Aug 2023, 3 years 1 month after primary completion. A results delay was requested in Jul 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VGX-3100
Squamous Intraepithelial Lesions →